Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
| ▸ | DPYD | Q12882 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968843 | 0.78 | DPYD (0.42) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| SCHEMBL1967477 | 0.78 | PNMT (0.39) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| SCHEMBL25949613 | 0.73 | NISCH (0.38) | HTR2AHTR2CHTR2BPNMTNISCH | |
| SCHEMBL21672157 | 0.69 | NISCH (0.35) | HTR2AHTR2CHTR2BPNMTNISCH | |
| SCHEMBL21743160 | 0.69 | NISCH (0.39) | PNMTNISCHKDM4EHTR5ANR2E1 | |
| SCHEMBL15848407 | 0.65 | PNMT (0.41) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| SCHEMBL29586892 | 0.65 | CD44 (0.58) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| SCHEMBL1010480 | 0.65 | CD44 (0.58) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| SCHEMBL21994457 | 0.65 | SOS1 (0.34) | HTR2AHTR2CHTR2BPNMTDRD2 | |
| Hydrochloric Acid SCHEMBL3070177 | 0.64 | CD44 (0.56) | HTR2AHTR2CHTR2BPNMTDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
| WO-2020198583-A1 | BICYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | HTR2A 3506/4885HTR2C 2815/4885HTR2B 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.